Table 4.
Areas under the curve of gliclazide serum concentrations (AUC), apparent volume of distribution (Vd), and blood glucose level (mmol/L) 240 seconds after and before intra-arterial gliclazide injection.
| Groups |
Mean ± SD | |||
|---|---|---|---|---|
| AUC (μg ∗ s ∗ mL−1) | Vd (mL) | Glucose level (mmol/L) | ||
| Before gliclazide | After gliclazide (240 s) | |||
| Group 1 healthy animals: gliclazide n = 6 |
4020.43 ± 456.42 | 219.73 ± 13.47 | 7.01 ± 0.3 | 9.55 ± 0.34** |
| Group 2 healthy animals: gliclazide + DA n = 6 |
3931.02 ± 1790.13 | 1077.19 ± 83.43* | 8.11 ± 0.60 | 9.53 ± 0.46** |
| Group 3 diabetic animals: gliclazide n = 6 |
2150.16 ± 1472.50 | 970.15 ± 79.97# | 29.04 ± 4.20 | 30.95 ± 3.86 |
| Group 4 diabetic animals: gliclazide + DA n = 6 |
1678.7 ± 415.21×× | 648.42 ± 203.65×× | 32.50 ± 5.75 | 34.3 ± 7.44 |
| Healthy animals | / | / | 7.7 ± 0.3 | 8.7 ± 0.35 |
| Diabetic animals | / | / | 28.83 ± 2.23 | 29.33 ± 2.19 |
| Healthy animals with DA pretreatment | / | / | 6.93 ± 0.6 | 7.45 ± 1.02 |
| Diabetic animals with DA pretreatment | / | / | 33.58 ± 4.02 | 29.7 ± 4.30 |
*Group 2 versus Group 1, P ≤ 0.05; ××Group 4 versus Group 1, P ≤ 0.05; #Group 3 versus Group 1, P ≤ 0.05; **glucose level before versus after gliclazide, P ≤ 0.05.